Exosome Diagnostics Appoints John Healy as Vice President of Informatics
Cambridge, Mass., May. 23, 2016 – Exosome Diagnostics, Inc., a developer of revolutionary biofluid-based molecular diagnostics, today announced the appointment of John Healy as its Vice President of Informatics.
“I am honored to join Exosome Diagnostics at such an exciting and pivotal time in the company’s growth, as they have created the next generation of biomarker discovery,” said John Healy. “Dr. Johan Skog and his team have developed the universal embodiment of non-invasive diagnostics; integrating RNA, DNA and protein makers in a single assay from any bio-fluid. With the ‘Academic Bench to Diagnostic Assay’ program, the companion diagnostics program, and regulatory framework currently in place, we are uniquely positioned to partner with large pharmaceutical companies and commercialize several exosomal RNA-based liquid biopsies in the near term, with the potential to improve patient care across multiple therapeutic areas.”
John Healy brings 20 years of experience in bioinformatics, biostatistics, genomics, software engineering and technology development. Prior to joining Exosome Diagnostics, John served as Vice President of Informatics at GnuBIO/Bio-Rad Laboratories, where he was responsible for building and leading both the bioinformatics and system software teams. Prior to that, John held various Senior Scientist and Project Lead roles at Life Technologies, Helicos BioSciences and Cold Spring Harbor Laboratory. He earned his Bachelor’s Degree in Computer Science and Applied Mathematics from Long Island University.
“John’s appointment to the Vice President of Informatics represents a critical step towards building a comprehensive pipeline that is able to generate new approaches to elucidate predictive markers derived from exosomal RNA and cell free DNA, built from years of proprietary analytical methodologies,” said John Boyce, CEO of Exosome Diagnostics. “John’s energy and cross- functional approach in working with Research and Development and Regulatory Affairs teams will rapidly generate a first rate informatics analysis engine.”
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLutionTM, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.
ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.
Feinstein Kean Healthcare